Current Effective Therapeutics in Management of COVID-19

doi:10.3390/jcm11133838

Review

. 2022 Jul 1;11(13):3838.

doi: 10.3390/jcm11133838.

Current Effective Therapeutics in Management of COVID-19

Kavya Atluri¹, Iris Aimlin², Shitij Arora³

Affiliations

¹ Department of Bioinformatics, University of California, Los Angeles, CA 90095, USA.
² Department of Internal Medicine, Montefiore Medical Center, New York, NY 10467, USA.
³ Department of Internal Medicine, Division of Hospital Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA.

PMID: 35807123
PMCID: PMC9267414
DOI: 10.3390/jcm11133838

Review

Current Effective Therapeutics in Management of COVID-19

Kavya Atluri et al. J Clin Med. 2022.

. 2022 Jul 1;11(13):3838.

doi: 10.3390/jcm11133838.

Authors

Kavya Atluri¹, Iris Aimlin², Shitij Arora³

Affiliations

¹ Department of Bioinformatics, University of California, Los Angeles, CA 90095, USA.
² Department of Internal Medicine, Montefiore Medical Center, New York, NY 10467, USA.
³ Department of Internal Medicine, Division of Hospital Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA.

PMID: 35807123
PMCID: PMC9267414
DOI: 10.3390/jcm11133838

Abstract

The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review.

Keywords: Anakinra; COVID-19; Casirivimab plus imdevimab; Sotrovimab; anticoagulation; baricitinib; bebtelovimab; coronavirus disease 2019; corticosteroids; evusheld; molnupiravir; monoclonal antibodies; omicron; paxlovid; remdesivir; therapeutics; timeline; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Therapeutic efficacies on Omicron sub-lineages.

**Figure 2**
Timeline of COVID-19 therapeutics and authorization use issuance at the FDA.

See this image and copyright information in PMC

Cited by

Efficacy and safety of oral antivirals in individuals aged 80 years or older with mild-to-moderate COVID-19: preliminary report from an Italian Prescriber Center.
Bruno G, Perelli S, Giotta M, Bartolomeo N, De Vita G, Buccoliero GB. Bruno G, et al. Infez Med. 2022 Dec 1;30(4):547-554. doi: 10.53854/liim-3004-9. eCollection 2022. Infez Med. 2022. PMID: 36482949 Free PMC article.
Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19.
Bruno G, Giotta M, Perelli S, De Vita G, Bartolomeo N, Buccoliero GB. Bruno G, et al. Viruses. 2022 Nov 14;14(11):2514. doi: 10.3390/v14112514. Viruses. 2022. PMID: 36423123 Free PMC article.
A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors.
Singh DD, Han I, Choi EH, Yadav DK. Singh DD, et al. Curr Issues Mol Biol. 2023 Jan 4;45(1):400-433. doi: 10.3390/cimb45010028. Curr Issues Mol Biol. 2023. PMID: 36661514 Free PMC article. Review.
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.
Arvanitis P, Lerner AH, Vieira K, Almaghlouth N, Farmakiotis D. Arvanitis P, et al. Clin Exp Med. 2023 Oct;23(6):2739-2748. doi: 10.1007/s10238-023-01019-y. Epub 2023 Feb 13. Clin Exp Med. 2023. PMID: 36780118 Free PMC article.
Repurposing an 'Old' Drug for the Treatment of COVID-19-Related Cytokine Storm.
Pontali E, Filauro F. Pontali E, et al. J Clin Med. 2023 May 10;12(10):3386. doi: 10.3390/jcm12103386. J Clin Med. 2023. PMID: 37240492 Free PMC article.

See all "Cited by" articles

References

1. CDC COVID Data Tracker. Centers for Disease Control and Prevention. [(accessed on 15 June 2022)]; Available online: https://covid.cdc.gov/covid-data-tracker/#datatracker-home.
1. World Health Organization WHO COVID-19 Dashboard. World Health Organization. Published 2022. [(accessed on 16 June 2022)]. Available online: https://covid19.who.int/
1. Gao Y.-D., Ding M., Dong X., Zhang J.-J., Azkur A.K., Azkur D., Gan H., Sun Y.-L., Fu W., Li W., et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428–455. doi: 10.1111/all.14657. - DOI - PubMed
1. Mahamat-Saleh Y., Fiolet T., Rebeaud M.E., Mulot M., Guihur A., El Fatouhi D., Laouali N., Peiffer-Smadja N., Aune D., Severi G. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: A systematic review and meta-analysis of observational studies. BMJ Open. 2021;11:e052777. doi: 10.1136/bmjopen-2021-052777. - DOI - PMC - PubMed
1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. [(accessed on 18 May 2022)];Cell Res. 2020 30:269–271. doi: 10.1038/s41422-020-0282-0. Available online: https://www.ncbi.nlm.nih.gov/pubmed/32020029. - DOI - PMC - PubMed

Publication types

Actions

Grants and funding

This research received no external funding.

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] CDC COVID Data Tracker. Centers for Disease Control and Prevention. [(accessed on 15 June 2022)]; Available online: https://covid.cdc.gov/covid-data-tracker/#datatracker-home.

[2] CDC COVID Data Tracker. Centers for Disease Control and Prevention. [(accessed on 15 June 2022)]; Available online: https://covid.cdc.gov/covid-data-tracker/#datatracker-home.

[3] World Health Organization WHO COVID-19 Dashboard. World Health Organization. Published 2022. [(accessed on 16 June 2022)]. Available online: https://covid19.who.int/

[4] World Health Organization WHO COVID-19 Dashboard. World Health Organization. Published 2022. [(accessed on 16 June 2022)]. Available online: https://covid19.who.int/

[5] Gao Y.-D., Ding M., Dong X., Zhang J.-J., Azkur A.K., Azkur D., Gan H., Sun Y.-L., Fu W., Li W., et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428–455. doi: 10.1111/all.14657. - DOI - PubMed

[6] Gao Y.-D., Ding M., Dong X., Zhang J.-J., Azkur A.K., Azkur D., Gan H., Sun Y.-L., Fu W., Li W., et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428–455. doi: 10.1111/all.14657. - DOI - PubMed

[7] Mahamat-Saleh Y., Fiolet T., Rebeaud M.E., Mulot M., Guihur A., El Fatouhi D., Laouali N., Peiffer-Smadja N., Aune D., Severi G. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: A systematic review and meta-analysis of observational studies. BMJ Open. 2021;11:e052777. doi: 10.1136/bmjopen-2021-052777. - DOI - PMC - PubMed

[8] Mahamat-Saleh Y., Fiolet T., Rebeaud M.E., Mulot M., Guihur A., El Fatouhi D., Laouali N., Peiffer-Smadja N., Aune D., Severi G. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: A systematic review and meta-analysis of observational studies. BMJ Open. 2021;11:e052777. doi: 10.1136/bmjopen-2021-052777. - DOI - PMC - PubMed

[9] Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. [(accessed on 18 May 2022)];Cell Res. 2020 30:269–271. doi: 10.1038/s41422-020-0282-0. Available online: https://www.ncbi.nlm.nih.gov/pubmed/32020029. - DOI - PMC - PubMed

[10] Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. [(accessed on 18 May 2022)];Cell Res. 2020 30:269–271. doi: 10.1038/s41422-020-0282-0. Available online: https://www.ncbi.nlm.nih.gov/pubmed/32020029. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current Effective Therapeutics in Management of COVID-19

Affiliations

Current Effective Therapeutics in Management of COVID-19

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous